化合物 KX2-391|T6345|TargetMol

Tirbanibulin
897016-82-9

￥243 1mg 起订

￥339 2mg 起订

￥523 5mg 起订

上海更新日期：2024-09-29

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 KX2-391

英文名称：: Tirbanibulin

CAS号：: 897016-82-9

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.67%

产品类别：: 抑制剂

货号：: T6345

Product Introduction

Bioactivity

名称	Tirbanibulin
描述	Tirbanibulin (KX2-391) is a highly selective Src kinase inhibitor that has demonstrated efficacy in pre-Clinicalal animal models of colon, pancreatic, prostate and breast cancer. It is a substrate-targeted kinase inhibitor. KX2-391, belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.
细胞实验	Liver cell lines including Huh7, PLC/PRF/5, Hep3B, and HepG2 (NutriCyte, Buffalo, NY) are routinely cultured and maintained in basal medium containing 2% fetal bovine serum (FBS) at 37 °C and 5% CO2. Cells are seeded at 4.0 × 103/190 μL and 8.0 × 103/190 μL per well of 96-well plate in basal medium containing 1.5% FBS. These are cultured overnight at 37 °C and 5% CO2 prior to the addition of KX2-391, at concentrations ranging from 6,564 to 0.012 nM in triplicates. Treated cells are incubated for 3 days. Ten microliters of 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/mL) is then added to each well on day 3 and cells incubated for 4 hours. The formazan product is dissolved with 10% SDS in dilute HCl. Optical density at 570 nm is measured by using BioTek Synergy HT multiplatform microplate reader. For comparison of activity and potency, parallel experiments are performed using KX2-391. Growth inhibition curves, 50% inhibition concentration (GI50), and 80% inhibition concentration (GI80) are determined using GraphPad Prism 5 statistical software. Data are normalized to represent percentage of maximum response as well as reported in optical density at wavelength of 570 nm (OD570) signal format.</ (Only for Reference)
体外活性	Tirbanibulin是一种针对Src底物口袋的Src抑制剂。在四种肝细胞癌（HCC）细胞系—Huh7（GI 50 = 9 nM）、PLC/PRF/5（GI 50 = 13 nM）、Hep3B（GI 50 = 26 nM）和HepG2（GI 50 = 60 nM）—中，Tirbanibulin展示了陡峭的剂量-响应曲线。[1] Tirbanibulin还被发现能抑制某些对当前市售药物具有抗性的白血病细胞，如带有T3151突变的慢性白血病细胞。在NIH3T3/c-Src527F和SYF/c-Src527F细胞的工程化Src驱动细胞增长评估中，Tirbanibulin分别显示出23 nM和39 nM的GI50。[2]
体内活性	在临床前的癌症动物模型中，口服KX2-391能够抑制原发性肿瘤生长并抑制转移。[2]
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 80 mg/mL (185.4 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble)
关键字	Microtubule/Tubulin \| Inhibitor \| inhibit \| KX 01 \| Tirbanibulin \| Src \| KX01
相关产品	4-Isopropoxybenzoic acid \| Mebendazole \| Flubendazole \| Oxfendazole \| Methylene Blue \| Methylene Blue trihydrate \| Griseofulvin \| N-Phenylbenzylamine \| Nintedanib \| Paclitaxel \| 4'-Demethylepipodophyllotoxin \| Ibrutinib
相关库	抑制剂库 \| 抗癌活性化合物库 \| 经典已知活性库 \| 已知活性化合物库 \| EMA 上市药物库 \| FDA 上市药物库 \| 微管靶向化合物库 \| 酪氨酸激酶分子库 \| 抗癌临床化合物库 \| 抗癌药物库

KX2-391|||KX-01|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务